Overall, our study supports previous researches indicating GSKJ4 as a promising therapeutic agent in Notch1- and TAL1- dependent T-ALL (19, 21), while laying the basis for extending its potential use also to Notch3- and c-Myc- dependent T-cell leukemia contexts. Here, MYC is linked to T-cell leukemia.